These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33326815)

  • 1. Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis.
    Avanceña ALV; Miller N; Uttal SE; Hutton DW; Mellinger JL
    J Hepatol; 2021 Jun; 74(6):1286-1294. PubMed ID: 33326815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness Analysis of Genotype-Guided Treatment Allocation in Patients with Alcohol Use Disorders Using Naltrexone or Acamprosate, Using a Modeling Approach.
    Sluiter RL; Kievit W; van der Wilt GJ; Schene AH; Teichert M; Coenen MJH; Schellekens A
    Eur Addict Res; 2018; 24(5):245-254. PubMed ID: 30384381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients.
    Zarkin GA; Bray JW; Aldridge A; Mitra D; Mills MJ; Couper DJ; Cisler RA;
    Arch Gen Psychiatry; 2008 Oct; 65(10):1214-21. PubMed ID: 18838638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revisiting the cost-effectiveness of the COMBINE study for alcohol dependent patients: the patient perspective.
    Dunlap LJ; Zarkin GA; Bray JW; Mills M; Kivlahan DR; McKay JR; Latham P; Tonigan JS
    Med Care; 2010 Apr; 48(4):306-13. PubMed ID: 20355261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Cost Effectiveness of Nalmefene for Reduction of Alcohol Consumption in Alcohol-Dependent Patients with High or Very High Drinking-Risk Levels from a UK Societal Perspective.
    Brodtkorb TH; Bell M; Irving AH; Laramée P
    CNS Drugs; 2016 Feb; 30(2):163-77. PubMed ID: 26879458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence.
    Baser O; Chalk M; Rawson R; Gastfriend DR
    Am J Manag Care; 2011 Jun; 17 Suppl 8():S222-34. PubMed ID: 21761948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of healthcare utilization among patients treated with alcoholism medications.
    Mark TL; Montejano LB; Kranzler HR; Chalk M; Gastfriend DR
    Am J Manag Care; 2010; 16(12):879-88. PubMed ID: 21348558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate.
    Palmer AJ; Neeser K; Weiss C; Brandt A; Comte S; Fox M
    Alcohol Alcohol; 2000; 35(5):478-92. PubMed ID: 11022023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.
    Palpacuer C; Duprez R; Huneau A; Locher C; Boussageon R; Laviolle B; Naudet F
    Addiction; 2018 Feb; 113(2):220-237. PubMed ID: 28940866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New pharmacotherapies for alcohol dependence: are they being used and what do they cost?
    Doran CM; Fawcett JE; Shakeshaft AP; Shanahan MD; Mattick RP
    Med J Aust; 2003 Aug; 179(4):218. PubMed ID: 12914502
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of alcohol use disorder in patients with liver disease.
    Nielsen AS; Askgaard G; Thiele M
    Curr Opin Pharmacol; 2022 Feb; 62():145-151. PubMed ID: 34999372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acamprosate. Pharmacoeconomic implications of therapy.
    Foster RH; McClellan KJ
    Pharmacoeconomics; 1999 Dec; 16(6):743-55. PubMed ID: 10724798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation-wide cohort of 125 556 patients.
    Heikkinen M; Taipale H; Tanskanen A; Mittendorfer-Rutz E; Lähteenvuo M; Tiihonen J
    Addiction; 2021 Aug; 116(8):1990-1998. PubMed ID: 33394527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disorders.
    Gastfriend DR
    Ann N Y Acad Sci; 2014 Oct; 1327(1):112-30. PubMed ID: 25236185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis.
    Rabiee A; Mahmud N; Falker C; Garcia-Tsao G; Taddei T; Kaplan DE
    Hepatol Commun; 2023 Apr; 7(4):. PubMed ID: 36972386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study characteristics influence the efficacy of substance abuse treatments: A meta-analysis of medications for alcohol use disorder.
    Klemperer EM; Hughes JR; Naud S
    Drug Alcohol Depend; 2018 Sep; 190():229-234. PubMed ID: 30059816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medications for Alcohol Use Disorder.
    Poorman E; McQuade BM; Messmer S
    Am Fam Physician; 2024 Jan; 109(1):71-78. PubMed ID: 38227873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New pharmacotherapies for alcohol dependence.
    Graham R; Wodak AD; Whelan G
    Med J Aust; 2002 Jul; 177(2):103-7. PubMed ID: 12098353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of alcohol treatment on social costs of alcohol dependence: results from the COMBINE study.
    Zarkin GA; Bray JW; Aldridge A; Mills M; Cisler RA; Couper D; McKay JR; O'Malley S
    Med Care; 2010 May; 48(5):396-401. PubMed ID: 20393362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alcohol pharmacotherapy dispensing trends in Australia between 2006 and 2023.
    Quintrell E; Page A; Wyrwoll C; Larcombe A; Preen DB; Almeida O; Etherton-Beer C; Kelty E
    Alcohol Alcohol; 2024 Jul; 59(5):. PubMed ID: 39242103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.